Glioblastoma: could there be new treatments for this cancer?

Glioblastoma is a type of brain cancer that spreads very quickly and it is usually very aggressive. This cancer arises from cells located in the brain called “astrocytes”. Since it grows very quickly, symptoms like constant headaches, seizures, blurred vision, vomiting and blurred vision, are commonly present. To diagnose adequately this disease, patients undergo a CT or MRI scan. Until now, there are no treatments to totally cure this disease. Usually, doctors perform surgery if the tumor is operable. Patients may also require radiation and chemotherapy as a treatment. The survival for cancer is improving, but for brain cancers it is still going slow because of the blood brain barrier obstacle. The blood brain barrier prevents drugs from reaching the tumor to attack it.

Recently, there has been more research in therapies that target this cancer. For example, researchers at several universities have been doing experiments using modified forms of poliovirus or the Zika virus. The studies have shown that tumor growth can be slowed down. There are also pharmaceutical companies, like AstraZeneca, that are working on research treatments. For example, AstraZeneca’s Lynparza works by inhibiting an enzyme (PARP) that allows cancer cells to repair their DNA damage and continue to proliferate. The results for the trials done with this molecule have been good, so there are more trials planned ahead using this new therapy along with chemotherapy and radiotherapy.

Althian is aware of the need to address this disease. We have worked with patients who suffer from glioblastoma and other types of brain cancer. We have witnessed the lack of treatment options for them. We are committed to improving a person’s overall health and if new clinical trials come along to treat glioblastoma and other brain cancers, we would be glad to be participating in those trials. If you want to know more about our experience with glioblastoma and other forms of brain cancer, contact us and we’ll be glad to share our stories.